



Ajinomoto Co., Inc. IR Day

Evolution of Governance to Enhance Corporate Value

Kimie Iwata Director Chair of the Board George Nakayama

Director Chair of the Nomination Committee

September 4, 2023

- **1** Introduction of Directors Kimie Iwata and George Nakayama
- **2** Board of Director's Role in Enhancing Corporate Value
- **3** Initiatives to Increase the Effectiveness
- 4 Expanding Deliberations by the Board of Directors
- 5 Purpose-Driven Management by

Medium-Term ASV Initiatives 2030 Roadmap

6 Toward the Future





1. Introduction of the Presenters

Kimie Iwata



Ajinomoto Co., Inc. Outside Director Chair of the Board Member of the Nomination Committee and the Compensation Committee

- 1947 Born in Takamatsu, Kagawa, Japan
- 1971 Joined the Ministry of Labour (currently Ministry of Health, Labour and Welfare)
- 2001 Director-General of Equal Employment, Children and Families Bureau, Ministry of Health, Labour and Welfare
- 2004 Director, Corporate Officer, Shiseido Company, Limited
- 2008 Representative Director, Executive Vice President, Shiseido Company, Limited
- 2012 Outside Audit & Supervisory Board Member, Kirin Holdings Company, Limited

Director, Shiseido Company, Limited

Outside Director, Japan Airlines Co., Ltd.

- 2015 Audit and Inspection Commissioner, the Tokyo Metropolitan Government (current position)
- 2016 Outside Director, Kirin Holdings Company, Limited
- 2018 Outside Director, Sumitomo Corporation (current position)
- 2019 Outside Director, Resona Holdings, Inc. (current position)

Outside Director, Ajinomoto Co., Inc. (current position)

Other current positions

- · Chair, Kanagawa Prefecture Gender Equality Council
- Member, Management Council of Niigata University
- Director, CARE International Japan



George Nakayama



Ajinomoto Co., Inc. Outside Director Chair of the Nomination Committee Member of the Compensation Committee and the Audit Committee May 1950 Born

Apr. 1979 Joined Suntory Limited

Mar. 2000 Director, Suntory Limited

Dec. 2002 President, CEO, Daiichi Suntory Pharma Co., Ltd.

June 2003 Director, Daiichi Pharmaceutical Co., Ltd.

June 2010 Representative Director, President, CEO, Daiichi Sankyo Co., Ltd.

Apr. 2017 Representative Director, Chairman, CEO, Daiichi Sankyo Co., Ltd.

June 2019 Representative Director, Chairman, Daiichi Sankyo Co., Ltd.

June 2020 Full-time Advisor, Daiichi Sankyo Co., Ltd. (current position)

June 2021 Independent Outside Director, Ajinomoto Co., Inc. (current position)



The Effectiveness of our Board of Directors:

The degree to which the Board of Directors is able to properly fulfill its purposes: discussing and examining key management matters that significantly affect corporate value, encouraging risk-taking in execution by indicating major directions, verifying the validity of execution processes and outcomes, and appropriately supervising execution.



Under a highly effective Board of Directors and governance structure, we will connect the above to the enhancement of corporate value.



Seven important management issues under ASV management

- 1. Corporate value (the ASV value creation cycle starting from intangible assets)
- 2. Capital policy, balance sheet optimization, shareholder return
- 3. Decision-making process, governance system design, establishment, policy, and operation
- 4. Medium-Term Management Plan and other management plans
- 5. Restructuring of the business portfolio, including withdrawal from some businesses
- 6. Large-scale M&A
- 7. Large-scale investment

Please refer to the following video streaming (webinar).

https://www.video-streaming.net/ir/2802/230904_irday_e/

